Parkinson's Disease and the Gut Microbiome in Rural CaliforniaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the gut microbiome of 96 Parkinson's disease patients to 74 controls in a rural California community. They looked for taxa and functional pathways linked to disease status and to PD-specific clinical features.
How was it studied?
Fecal samples underwent 16S rRNA gene sequencing to measure microbial diversity, taxa abundance, and predicted Metacyc functional pathways. Associations were adjusted for sex, race, age, and sequencing platform, then tested against disease duration, motor subtype, L-DOPA dose, and motor function.
What did they find?
PD patients had lower species diversity (p = 0.04) and a compositionally distinct microbiome (p = 0.002), with higher Proteobacteria, Verrucomicrobiota, and Actinobacteria, plus higher Akkermansia, Enterococcus, Hungatella, and two Ruminococcaceae genera. Thirty-five Metacyc pathways were predicted to differ, and the postural instability gait dysfunction subtype tracked with three phyla and the NAD biosynthesis pathway, while disease duration tracked with the Synergistota phylum, six genera, and aromatic compound degradation pathways.
Why it matters
The findings tie specific gut bacteria and metabolic pathways to Parkinson's clinical features like motor subtype and disease duration, not just PD status alone. This points to microbial pathways worth investigating for tracking or influencing PD progression.